We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




A Single-Cell RNA-Sequencing-Based Non-Invasive Screening Tool for Endometriosis

By LabMedica International staff writers
Posted on 21 Sep 2022

Results presented in a recent paper lay the ground work for using menstrual effluent (ME) as an effective screening tool for identifying endometriosis in patients with chronic symptoms suggestive of this disorder. More...

Endometriosis is a disorder that occurs when uterine-like tissues grow outside of the uterus and form lesions. The condition affects about 10% of reproductive-age females, resulting in chronic, often debilitating pain or infertility and other medical complications. Due to the lack of non-surgical diagnostic tools, it can often take seven to 10 years to be diagnosed with endometriosis. Currently, invasive laparoscopic surgery is the only definitive diagnostic method.

Investigators at The Feinstein Institutes for Medical Research (Manhasset, NY, USA) evaluated the potential of fresh ME, which contains large numbers of shed fragments from endometrial tissues, as an unexplored and important biological specimen for the development of non-invasive diagnostics based on the direct analysis of these endometrial tissue fragments.

In this study, the investigators performed the first single-cell RNA-sequencing (scRNA-Seq) comparison of endometrial tissues in freshly collected ME from 33 subjects, including confirmed endometriosis patients (cases) and controls as well as symptomatic subjects (who have chronic symptoms suggestive of endometriosis but have not been diagnosed). The investigators carried out enzymatic digestion of ME and associated tissues followed by scRNA-Seq analysis and compared the major cellular differences and gene expression profiles found in ME collected from healthy controls and patients diagnosed with endometriosis, as well as patients with symptoms of endometriosis who were not yet diagnosed.

The RNA analysis identified a unique subcluster of proliferating uterine natural killer (uNK) cells in ME-tissues from controls that was almost absent from endometriosis cases, along with a striking reduction of total uNK cells in the ME of cases. In addition, a decidualized subset of endometrial stromal cells was abundant in the shed endometrium of controls when compared to cases, confirming findings of compromised decidualization of cultured stromal cells from cases. Decidualized cells are surrounded by a mucous membrane that lines the uterus and is shed during menstruation and modified during pregnancy.

In addition, an enrichment of B-cells in the cases raised the possibility that some of these patients may have chronic endometritis, a disorder which often progresses to endometriosis.

“Millions of adolescents and women suffer from endometriosis without a proper diagnosis, delaying their care and extending their pain,” said contributing author Dr. Christine Metz, professor of molecular medicine at the Feinstein Institutes for Medical Research. “This new paper describes the potential for a novel screening tool to identify endometriosis earlier and enable patients to get the help they need.”

The endometriosis paper was published in the September 15, 2022, online edition of the journal BMC Medicine.

Related Links:
The Feinstein Institutes for Medical Research 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.